Literature DB >> 21677919

Non-cystic fibrosis bronchiectasis.

M P Smith1.   

Abstract

Bronchiectasis is a chronic debilitating condition. Pathologically, a vicious cycle of infection and inflammation exists in the permanently damaged airways with patients suffering a persistent cough, chronic daily sputum production and recurrent chest infections. Once termed an 'orphan disease', the prevalence of bronchiectasis has become increasingly recognised over the past few decades. The associated burden of disease in terms of respiratory morbidity, effect on patients' health-related quality of life and the economic cost of long term management is significant and it has become apparent that more research into its causes and management is urgently needed. This article reviews what is currently known about bronchiectasis, its pathophysiology, aetiology and management strategies.

Entities:  

Mesh:

Year:  2011        PMID: 21677919     DOI: 10.4997/JRCPE.2011.217

Source DB:  PubMed          Journal:  J R Coll Physicians Edinb        ISSN: 1478-2715


  5 in total

1.  Non-tuberculous mycobacterial disease is common in patients with non-cystic fibrosis bronchiectasis.

Authors:  Mehdi Mirsaeidi; Walid Hadid; Basel Ericsoussi; Daniel Rodgers; Ruxana T Sadikot
Journal:  Int J Infect Dis       Date:  2013-05-16       Impact factor: 3.623

2.  Development of Inhalable Nanostructured Lipid Carriers for Ciprofloxacin for Noncystic Fibrosis Bronchiectasis Treatment.

Authors:  Alanood S Almurshedi; Basmah N Aldosari; Hessah A Aljunaidel; Bushra Alquadeib; Iman M Alfagih; Salma S Almarshidy; Eram K D Eltahir; Amany Z Mohamoud
Journal:  Int J Nanomedicine       Date:  2021-03-25

3.  Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study.

Authors:  Robert Wilson; Tobias Welte; Eva Polverino; Anthony De Soyza; Hugh Greville; Anne O'Donnell; Jeff Alder; Peter Reimnitz; Barbara Hampel
Journal:  Eur Respir J       Date:  2012-09-27       Impact factor: 16.671

4.  Impact of Long-Term Erythromycin Therapy on the Oropharyngeal Microbiome and Resistance Gene Reservoir in Non-Cystic Fibrosis Bronchiectasis.

Authors:  Jocelyn M Choo; Guy C J Abell; Rachel Thomson; Lucy Morgan; Grant Waterer; David L Gordon; Steven L Taylor; Lex E X Leong; Steve L Wesselingh; Lucy D Burr; Geraint B Rogers
Journal:  mSphere       Date:  2018-04-18       Impact factor: 4.389

5.  A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults with bronchiectasis: a protocol for the CLEAR clinical trial.

Authors:  Judy Martina Bradley; Rohan Anand; Brenda O'Neill; Kathryn Ferguson; Mike Clarke; Mary Carroll; James Chalmers; Anthony De Soyza; Jamie Duckers; Adam T Hill; Michael R Loebinger; Fiona Copeland; Evie Gardner; Christina Campbell; Ashley Agus; Alistair McGuire; Roisin Boyle; Fionnuala McKinney; Naomi Dickson; Danny F McAuley; Stuart Elborn
Journal:  Trials       Date:  2019-12-19       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.